| Similar Articles |
|---|
 |
The Motley Fool
August 28, 2007
Brian Orelli |
FDA Makes Cows Happy The FDA approves Omrix's human-derived thrombin, which replaces a version made from cattle.   |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA. |
Managed Care
January 2007 |
New Coagulant Bypasses Clotting Dysfunction in Hemophilia The less common form of hemophilia - acquired hemophilia - can now be treated with recombinant activated factor VII. |
The Motley Fool
August 21, 2009
Brian Orelli |
ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
The Motley Fool
August 23, 2007
Brian Orelli |
Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting. |
The Motley Fool
May 13, 2008
Brian Orelli |
Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows. |
Chemistry World
March 31, 2009
Jon Cartwright |
Blood clotting light work for new molecule The molecule, which works with the help of an enzyme, could one day be used in medicine to shut off blood supply to localized areas of the human body such as tumors. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Acute Coronary Syndrome A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation. |
